Institution
Northern General Hospital
Healthcare•Sheffield, United Kingdom•
About: Northern General Hospital is a healthcare organization based out in Sheffield, United Kingdom. It is known for research contribution in the topics: Population & Osteoporosis. The organization has 4264 authors who have published 4865 publications receiving 173014 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: The guidelines focused on 4 key domains: (1) AKI definition, (2) prevention and treatment of AKI, (3) contrastinduced AKI (CI-AKI) and (4) dialysis interventions for the treatment ofAKI.
Abstract: tion’, implying that most patients ‘should’ receive a particular action. In contrast, level 2 guidelines are essentially ‘suggestions’ and are deemed to be ‘weak’ or discretionary, recognising that management decisions may vary in different clinical contexts. Each recommendation was further graded from A to D by the quality of evidence underpinning them, with grade A referring to a high quality of evidence whilst grade D recognised a ‘very low’ evidence base. The overall strength and quality of the supporting evidence is summarised in table 1 . The guidelines focused on 4 key domains: (1) AKI definition, (2) prevention and treatment of AKI, (3) contrastinduced AKI (CI-AKI) and (4) dialysis interventions for the treatment of AKI. The full summary of clinical practice statements is available at www.kdigo.org, but a few key recommendation statements will be highlighted here.
6,247 citations
Imperial College London1, University of Barcelona2, Keio University3, University of Duisburg-Essen4, Queen's University5, Peter MacCallum Cancer Centre6, University of Michigan7, University of São Paulo8, Yale University9, Northern General Hospital10, University of Caen Lower Normandy11, Fred Hutchinson Cancer Research Center12, University of Oxford13, Memorial Sloan Kettering Cancer Center14, University of Sydney15, Sungkyunkwan University16, Seoul National University17, Kyorin University18, University of Copenhagen19, Nippon Medical School20, Katholieke Universiteit Leuven21, University of Texas MD Anderson Cancer Center22, University of Antwerp23, Hyogo College of Medicine24, University of Western Australia25, Glenfield Hospital26, Cleveland Clinic27, Icahn School of Medicine at Mount Sinai28, University of Turin29, Université libre de Bruxelles30, Juntendo University31, National Cancer Research Institute32, Mayo Clinic33, University of Toronto34, Sinai Grace Hospital35, Netherlands Cancer Institute36, Hiroshima University37, City of Hope National Medical Center38, University of Chicago39, New York University40, Georgetown University41, University of Tokushima42, University of Pisa43, Osaka University44, University of Valencia45, Good Samaritan Hospital46, Military Medical Academy47, Fundación Favaloro48, Autonomous University of Barcelona49, Complutense University of Madrid50, University of Oviedo51, National and Kapodistrian University of Athens52, Rovira i Virgili University53, Autonomous University of Madrid54, Ghent University55
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
2,826 citations
University of Cambridge1, University of Birmingham2, Southampton General Hospital3, Humboldt University of Berlin4, Karolinska Institutet5, University of Cagliari6, United States Military Academy7, Baylor College of Medicine8, Wellcome Trust Sanger Institute9, University of Helsinki10, Northern General Hospital11, University of Bristol12, University of Oslo13, Norwegian Institute of Public Health14, Queen's University Belfast15, Merck & Co.16
TL;DR: In this article, the authors identify polymorphisms of the cytotoxic T lymphocyte antigen 4 gene (CTLA4) as candidates for primary determinants of risk of the common autoimmune disorders Graves' disease, autoimmune hypothyroidism and type 1 diabetes.
Abstract: Genes and mechanisms involved in common complex diseases, such as the autoimmune disorders that affect approximately 5% of the population, remain obscure. Here we identify polymorphisms of the cytotoxic T lymphocyte antigen 4 gene (CTLA4)—which encodes a vital negative regulatory molecule of the immune system—as candidates for primary determinants of risk of the common autoimmune disorders Graves' disease, autoimmune hypothyroidism and type 1 diabetes. In humans, disease susceptibility was mapped to a non-coding 6.1?kb 3′ region of CTLA4, the common allelic variation of which was correlated with lower messenger RNA levels of the soluble alternative splice form of CTLA4. In the mouse model of type 1 diabetes, susceptibility was also associated with variation in CTLA-4 gene splicing with reduced production of a splice form encoding a molecule lacking the CD80/CD86 ligand-binding domain. Genetic mapping of variants conferring a small disease risk can identify pathways in complex disorders, as exemplified by our discovery of inherited, quantitative alterations of CTLA4 contributing to autoimmune tissue destruction.
2,173 citations
TL;DR: The models provide a framework which enhances the assessment of fracture risk in both men and women by the integration of clinical risk factors alone and/or in combination with BMD.
Abstract: Summary
A fracture risk assessment tool (FRAX™) is developed based on the use of clinical risk factors with or without bone mineral density tests applied to the UK.
2,107 citations
TL;DR: When designing a clinical trial an appropriate justification for the sample size should be provided in the protocol, but there are a number of settings when undertaking a pilot trial when there is no prior information to base a sample size on.
Abstract: When designing a clinical trial an appropriate justification for the sample size should be provided in the protocol. However, there are a number of settings when undertaking a pilot trial when there is no prior information to base a sample size on. For such pilot studies the recommendation is a sample size of 12 per group. The justifications for this sample size are based on rationale about feasibility; precision about the mean and variance; and regulatory considerations. The context of the justifications are that future studies will use the information from the pilot in their design. Copyright © 2005 John Wiley & Sons, Ltd.
1,624 citations
Authors
Showing all 4271 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Giulio Gabbiani | 104 | 346 | 47497 |
| Richard Eastell | 100 | 452 | 38530 |
| Stuart H. Ralston | 96 | 455 | 29999 |
| Alex J. Sutton | 95 | 307 | 47411 |
| Eugene V. McCloskey | 94 | 544 | 41223 |
| Alkes L. Price | 89 | 253 | 66704 |
| Freddie C. Hamdy | 86 | 556 | 28816 |
| Robert F. Storey | 83 | 430 | 48760 |
| John R. Geddes | 83 | 441 | 37064 |
| Mark Stevenson | 81 | 1142 | 32820 |
| Simon Capewell | 80 | 474 | 29354 |
| Michael J. Campbell | 80 | 412 | 28875 |
| Gianni D Angelini | 79 | 736 | 25458 |
| Simon S. Cross | 78 | 332 | 24193 |
| Andrew P. Selwyn | 77 | 268 | 26507 |